CD274 and non-small cell lung carcinoma: (c)As four phase III trials comparing platinum-based chemotherapy plus PD-1/PD-L1 inhibitor with platinum-based chemotherapy allowed enrollment of patients with PS 0–1, there are no efficacy or safety data of platinum-based chemotherapy plus PD-1/PD-L1 inhibitor in stage IV NSCLC patients with PS 2.